Protection against chemotherapy toxicity by iv hyperalimentation

B. F. Issell, M. Valdivieso, Howard A. Zaren, S. J. Dudrick, E. J. Freireich, E. W. Copeland, G. P. Bodey

Research output: Contribution to journalArticlepeer-review

83 Scopus citations

Abstract

A prospective randomized trial was conducted comparing the addition of iv hyperalimentation (IVH) to Corynebacterium parvum, isophosphamide, and adriamycin (CIA) chemoimmunotherapy in 26 patients with extensive squamous cell lung cancer. Thirteen patients were entered in each treatment arm of the study and IVH was administered before and after the first course of CIA for a total of 31 days. The major dose-limiting toxic effect of CIA was leukopenia. Less myelosuppression was observed for the patients receiving IVH. The difference in the lowest recorded leukocyte and neutrophil counts between the two groups was significant (P = 0.03 and 0.01, respectively). Also, a significant decrease (P = 0.06) in nausea and vomiting associated with chemotherapy administration was found for the IVH group. The differences in toxic effects between each group were not maintained over subsequent courses of therapy when both groups received CIA alone. The prevention of the toxic effects of chemotherapy by IVH suggests a means of giving higher chemotherapy doses with the intent of increasing tumor response and patient survival.

Original languageEnglish (US)
Pages (from-to)1139-1143
Number of pages5
JournalCancer Treatment Reports
Volume62
Issue number8
StatePublished - Dec 1 1978

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Protection against chemotherapy toxicity by iv hyperalimentation'. Together they form a unique fingerprint.

Cite this